Wednesday, November 23, 2011

New Target Identified to Stop the Spread of Breast Cancer

A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of researchers led by Dr. Richard Kremer from the Research Institute of the McGill University Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused by the spread of the disease through metastasis to other parts of the body, most often to the bones and lungs.

A new potential target to slow breast cancer tumor progression and metastasis has been identified. (Credit: Image courtesy of McGill University Health Centre)
 

These findings, published this week in the Journal of Clinical Investigation (JCI), suggest that a specific protein plays a key role in the progression of the disease outside of the initial tumor area.

Researchers showed that this particular target called parathyroid hormone-related protein (PTHrP), present at high levels in cancers, is involved in key stages of breast cancer initiation, progression and metastatic spread. "We are hoping for a significant effect on the prevention of breast cancer recurrence, growth and development by using a strategy to decrease the production of that particular protein," says Dr. Richard Kremer, co-director of the Musculoskeletal Axis of the RI-MUHC and a professor in the Department of Medicine at McGill University.

To better understand the role of PTHrP in cancer development, researchers eliminated the production of the hormone from breast cells using a strategy called "conditional knockout" and then studied the progression of the tumor. "The results showed that without the presence of PTHrP in the breast, even before the tumor developed, a reduction of 80 to 90 per cent in the growth of the tumor was observed," explains Dr. Kremer. "The removal of this hormone in the breast and breast tumors block not only the growth of the tumors but also its spread to different organs."

In order to bring this strategy one step closer to the patient, Dr. Kremer and his team developed a monoclonal antibody against PTHrP -- a molecule that mimics the antibodies produced as part of the immune system's response to invaders, which is widely used in cancer treatment. Researchers were able to stop the growth of human breast tumors implanted in animal models and their metastatic spread, paving the way for clinical trials in the near future.

"This opens the door to treatment of patients with a more aggressive type of breast cancer who are not responsive to standard treatment," says Dr. Kremer. "I see a potential for better treatment of the disease and improvement in quality of life for a very significant number of patients."

 

1 comment:

  1. [...] Type of breast cancer: It is important to know! It is significant and important to know the type of...and important to know the type of breast cancer that has touched because, knowing what contributes greatly to your doctor get the best treatment for breast cancer and also for you to ask the right questions for understanding and working with your doctor about your treatment. target = "blank"> type of breast cancer: Ductal carcinoma in situ (DCIS) is a type of early breast cancer that is confined within the ductal system. Infiltrating ductal carcinoma (IDC): One of the most common types of breast cancer whose prognosis is 78% of malignant tumors. The lesions appear as saying that the stars stellate or round circumscribed areas on mammograms. Stellate lesions generally said to have a worse prognosis. Medullary carcinoma: medullary carcinoma is reported 15% of all cancers of the breast. This type of cancer breast is more frequent among women in their late 40s and 50s. Your mammogram shows cells resembling bone marrow that is the brain's gray matter. Lobular carcinoma (ILC): Infiltrating lobular carcinoma type of breast cancer usually appears as a subtle thickening in the upper outer quadrant of the breast. CIT breast cancer represents 5% of all diagnoses. If this type of breast cancer occurs, which are mainly positive for estrogen receptors and progesterone, and therefore the breast cancer tumors CDI type respond well to hormonal treatment. Tubular carcinoma: This type of breast cancer is approximately 2% of all breast cancer diagnoses. Tubular-type breast cancer cells have a characteristic tubular structure when viewed under a microscope. type of tubular carcinoma breast cancer is among women aged 50 years, but with treatment that has an excellent survival rate at 10 years of 95%. Mucinous carcinoma (colloid) carcinoma, mucinous breast cancer symptoms represents about 1% to 2% of all breast cancers. This type of breast cancer has a favorable prognosis in most cases. The main feature differentiation is the production of mucus cells that are not well defined. Inflammatory breast cancer (IBC): Although this type of cancer Inflammatory breast breast is rare type, but very aggressive breast cancer. So called because the breast often looks swollen and red, as if ignited, and all this happens because the lymph vessels in the skin of the breast tend to hang. IBC accounts for 1% to 5% of cases of breast cancer in the United States. About the Author [...]

    ReplyDelete